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640One-Antigen Mismatched Related versus HLA-Matched
Unrelated Donor Hematopoietic Stem Cell
Transplantation in Adults with Acute Leukemia: Center
for International Blood and Marrow Transplant
Research Results in the Era of Molecular HLA Typing
David Valca´rcel,1 Jorge Sierra,1 Tao Wang,2 Fangyu Kan,3,11 Vikas Gupta,4
Gregory A. Hale,5 David I. Marks,6 Philip L. McCarthy,7 Machteld Oudshoorn,8
Effie W. Petersdorf,9 Olle Ringde´n,10 Michelle Setterholm,11
Stephen R. Spellman,3,11 Edmund K. Waller,12 James L. Gajewski,13
Susana R. Marino,14 David Senitzer,15 Stephanie J. Lee9Approximately 13%of patients lacking anHLA-identical sibling have a one-antigen–mismatched related donor
(MMRD). Historically, outcomes from the use of a one-antigen MMRD were considered equivalent to those
from the use of a matched unrelated donor (UD). Recent improvements in UD stem cell transplantation
(SCT) resulting from better molecular HLA matching justifies investigating whether UD should be preferred
over MMRD in adult patients with acute leukemia. Here, we compared the outcomes of MMRD (n5 89) and
HLA-A, -B, -C, and -DRB1 allele–matched UD (n5 700) SCTreported to the Center for International Blood
and Marrow Transplant Research between 1995 and 2005. The patients underwent transplantation for acute
myelogenous leukemia or acute lymphoblastic leukemia in first or second complete remission. Donor type
was not associated with hematologic recovery. Univariate and multivariate comparisons of MMRD versus
HLA-matched UD transplants showed no statistically significant differences in overall survival, disease-free
survival, treatment-related mortality, relapse, or 100-day grade III-IV acute graft-versus-host disease
(GVHD).MMRDSCTwas associatedwith a lower rate of chronicGVHDat 1 year (35% vs 47%; P5.03), which
was confirmed by multivariate analysis (relative risk, 0.58; 95% confidence interval, 0.39-0.85; P\.01). Ac-
cording to our data, HLA-matched UD and MMRD SCT are associated with comparable survival. Given
that less chronic GVHD was observed in the MMRD transplantations, this option, when available, remains
the first choice in patients with acute leukemia without an HLA-identical sibling in need of allogeneic SCT.
Biol Blood Marrow Transplant 17: 640-648 (2011)  2011 American Society for Blood and Marrow TransplantationKEY WORDS: HLA match, Allogeneic transplantation, Acute myelogenous leukemia, Acute lymphoblastic
leukemiaINTRODUCTION
AlthoughHLA-identical siblings are considered the
optimal donors, they are available for only one-third or
fewer of patients with acute leukemia for whom alloge-1Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;
er for International Blood and Marrow Transplant
rch, Milwaukee, Wisconsin; 3Center for International
and Marrow Transplant Research, Minneapolis, Minne-
4Princess Margaret Hospital, Toronto, Canada; 5St Jude
ren’s Research Hospital, Memphis, Tennessee; 6Univer-
f Bristol, Bristol, UK; 7Rosewell Park Cancer Institute,
o New York; 8Euopdonor Foundation, Leiden, The
rlands; 9Fred Hutchinson Cancer Research Center,
e, Washington; 10Center for Allogeneic Stem Cell
plantation, Karolinska University, Stockholm, Sweden;
ional Marrow Donor Program, Minneapolis, Minnesota;neic stem cell transplantation (allo-SCT) is recommen-
ded. The probability of finding an HLA-A, -B, or -DR
antigen–mismatched related donor (MMRD) is approx-
imately 3% between siblings and 10% among other12Emory University, Atlanta, Georgia; 13Oregon Health &
Science University, Portland, Oregon; 14University of Chicago,
Chicago, Illinois; and 15City of Hope, Duarte, California.
Financial disclosure: See Acknowledgments on page 647.
Correspondence and reprint requests: David Valca´rcel, MD,
Hematology and Stem Cell Transplantation Department,
Hospital de la Santa Creu i Sant Pau, Mas Casanovas 90,
08025 Barcelona, Spain (e-mail: dvalcarcel@santpau.cat).
Received June 7, 2010; accepted July 26, 2010
 2011 American Society for Blood and Marrow Transplantation
1083-8791/$36.00
doi:10.1016/j.bbmt.2010.07.022
Biol Blood Marrow Transplant 17:640-648, 2011 641One-Antigen MMRD versus HLA-Matched URD in Acute Leukemiarelatives [1]. Another option for these patients is to un-
dergo a search for an unrelated donor (UD). The overall
probability of identifying anHLA-compatible unrelated
volunteer in the international registries is approximately
10%-75%, depending on the race and ethnicity of the
patient (http://www.marrow.org).
In recent years, survival after UD allo-SCT has im-
proved, mainly because of better matching of donor–
recipient pairs based onmolecular typing of HLA class
I and II loci [2-5]. Moreover, recent reports show
similar outcomes of allo-SCT in patients with an
HLA-matched UD and those with an HLA-identical
sibling donor [6-10].
The progress in the UD allo-SCT setting provides
the rationale for reexamining whether this option
should be recommended to patients with an available
MMRD. This question warrants investigation because
it is well recognized that HLA mismatch increases
graft failure and graft-versus-host disease (GVHD)
after transplantation. Given that previous comparisons
between UD and MMRD transplants were published
before the introduction of HLA typing at the allele
level [11-16], we reevaluated this question in recent
transplantations for patients with acute leukemia
included in the Center for International Blood and
Marrow Transplant Research (CIBMTR) database.PATIENTS AND METHODS
Data Collection
The data used in this study were obtained from the
CIBMTR’s Statistical Center. A research affiliate of the
International Bone Marrow Transplant Registry, the
Autologous Blood and Marrow Transplant Registry,
and the National Marrow Donor Program (NMDP),
the CIBMTR comprises a voluntary working group of
more than 450 transplantation centers worldwide that
contribute detailed data on consecutive allogeneic and
autologous hematopoietic SCTs to the Statistical Cen-
ter at the Medical College of Wisconsin in Milwaukee
and the NMDP Coordinating Center in Minneapolis.
Participating centers are required to report all trans-
plantations consecutively; compliance is monitored by
onsite audits. Patients are followed longitudinally with
yearly follow-up. Computerized checks for errors, phy-
sicians’ reviews of submitted data, and onsite audits of
participating centers ensure data quality. Observational
studies are conducted by the CIBMTRwith a waiver of
informed consent and in compliance withHIPAA regu-
lations as determined by the Medical College of Wis-
consin’s InstitutionalReviewBoard andPrivacyOfficer.Inclusion Criteria
The study population included 89 patients who
received an MMRD transplant and 700 patients whoreceived an 8/8 HLA-A, -B, -C, and -DRB1 allele–
matched UD transplant between 1995 and 2005.
This study was restricted to adult patients (18 years
or older), with a diagnosis of acute myelogenous leuke-
mia (AML) or acute lymphoblastic leukemia (ALL) in
first or second complete remission (CR1, CR2), who
underwent a first bone marrow or peripheral blood
SCTwith either myeloablative conditioning (MAC) or
reduced-intensity conditioning (RIC). T cell–depleted
cases were excluded. Informed consent was obtained
in accordance with the Declaration of Helsinki. All
surviving UD recipients included in this analysis
were retrospectively contacted and provided informed
consent for participation in the NMDP research pro-
gram. Informed consent was waived by the NMDP’s
Institutional Review Board for all deceased recipients.
Approximately 10% of surviving patients would not
provide consent for use of the research data. To
adjust for the potential bias introduced by exclusion
of nonconsenting surviving patients, a corrective ac-
tion plan modeling process was used to randomly ex-
clude approximately the same percentage of deceased
patients using a biased coin randomization with exclu-
sion probabilities based on characteristics associated
with not providing consent for the use of data in
survivors [17].
HLATyping
In the UD group, HLA typing consisted of high-
resolution typing of HLA-A, -B, -C, and -DRB1 al-
leles, verified through the NMDP retrospective typing
program as described previously [18]. For the purpose
of this study and in accordance with recent reports,
mismatches affecting only the HLA-DQ locus were
considered full matches [17,19]. In the MMRD
group, HLA typing was verified by reviewing HLA
typing reports and was restricted to low-resolution
typing of HLA-A, -B, and -DRB1 loci.
Endpoints
Theaimof the studywas tocompare the clinical out-
comes among patients with acute leukemia who
underwent a first SCT from a one-antigen MMRD or
from an HLA-matched UD, to determine which donor
typewas associatedwith better outcomes. Analyzed out-
comes were overall survival (OS), disease-free survival
(DFS), hematologic engraftment, incidence of acute
and chronic GVHD (aGVHD, cGVHD), incidence of
relapse, and treatment-related mortality (TRM).
The date of engraftment was defined as the first of
3 consecutive days with an absolute neutrophil count
(ANC) $0.5  109/L. Platelet engraftment was
defined as the achievement of a platelet count $20 
109/L without platelet transfusions in the previous 7
days. The aGVHD endpoint referred to the develop-
ment of grades II-IV and grades III-IV according to
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using established definitions [21]. Relapse was defined
as recurrence of leukemia, and TRM was defined as
death resulting from any cause other than relapse.
DFS was defined as survival in CR after SCT. For
OS, death from any cause was considered an event.
All living patients were censored at last follow-up. Dis-
ease was classified according to cytogenetic risk. For
AML, the Medical Research Council (MRC) [22]
and Southwest OncologyGroup [23] classification sys-
tems were used; in cases where there was a discrepancy,
the classification system that resulted in the higher risk
status was applied. For ALL, theMRC/Eastern Coop-
erative Oncology Group criteria were used [24].Statistical Analysis
Patient-, disease-, and transplant-related variables
were compared between the two groups using the c2
test for categorical variables and the Kruskal-Wallis
test for continuous variables. Hematopoietic recovery
and the occurrence of GVHD, TRM, and disease
relapse were calculated using cumulative incidence
estimates, taking into account the competing-risk
structure [25,26]. Probabilities of DFS and OS were
estimated from the time of transplantation using
Kaplan-Meier curves [27]. Groups were compared
using the two-sided log-rank test [25,26].
For the multivariate analysis, Cox proportional
hazards regression models were applied. The propor-
tional hazards assumption was assessed for each covari-
ate using a time-dependent covariate approach.
Covariates that violated the proportional hazard
assumption were adjusted by stratification. Stepwise
forward-backward selection was used to build the
models from the prognostic factors under consider-
ation. A threshold of .05 was used for the selection of
covariates. All analyses were performed using SAS
version 9.1 (SAS Institute, Cary, NC).RESULTS
Patient, Disease, and Transplant Characteristics
Patient characteristics are compiled in Table 1.
Compared with the HLA-matched UD group, the
MMRD group differed in the following characteristics
that have been associated with better outcome: younger
age, more favorable cytogenetics in ALL cases, greater
ABO matching between donor and patient, and more
frequent use of methotrexate. Some differences sug-
gested worse outcomes in theMMRDgroup, including
more frequent transplantations from a female donor to
amale recipient, older donor age, less common low-risk
cytomegalovirus (CMV) donor–recipient serologic
status, and lower percentage of patients undergoing
transplantation during the later period (2001-2005).The median follow-up for survivors in the MMRD
group was 54 months (range, 3-135 months), and that
for survivors in the HLA-matched UD group was 38
months (range, 10-149 months).Engraftment
The data for hematologic engraftment are given in
Table 2. The incidence of neutrophil engraftment at
28 days was 89% (95% confidence interval [CI],
81%-95%) for the MMRD group and 93% (95% CI,
91%-95%) for the HLA-matched UD group (P5 .21).
Among those who engrafted, the median time to
neutrophil engraftment (0.5  109/L) was 16 days after
MMRD allo-SCT and 15 days after HLA-matched
UD allo-SCT, and the median time to platelet engraft-
ment (20 109/L) was 18 days and 20 days, respectively.GVHD
The probability of grade II-IV aGVHDat 100 days
was 49% (95% CI, 38%-60%) in the MMRD group
and 47% (95% CI, 43%-51%) in the HLA-matched
UD group (Table 2). In multivariate analysis, donor
type was not associated with grade II-IV aGVHD (rel-
ative risk [RR], 1.11; 95% CI, 0.80-1.55; P 5 .53) or
with grade III-IV aGVHD (RR, 1.53; 95% CI, 0.91-
2.57; P 5 .11) (Table 3). The 1-year probability of
cGVHD after MMRD allo-SCT was 35% (95% CI,
25%-46%), compared with 47% (95% CI, 44%-
51%), after HLA-matched UD allo-SCT. The 1-year
probability of extensive cGVHD after MMRD allo-
SCT was 24% (95% CI, 15%-34%), compared with
36% (95% CI, 33%-40%) after HLA-matched UD
allo-SCT (P 5 .01). Multivariate analysis also showed
a significantly lower rate of cGVHD in the MMRD
group compared with the HLA-matched UD group
(RR, 0.58; 95% CI, 0.39-0.85; P \ .01) (Figure 1).
Unadjusted cumulative incidence curves of cGVHD
are shown in Figure 2.Relapse
The cumulative incidence of relapse was 15% (95%
CI, 8%-23%) at 1 year, 19% (95% CI, 11%-28%) at 2
years, and 20% (95% CI, 12%-29%) at 3 years after
MMRD allo-SCT, and 23% (95% CI, 20%-26%) at
1 year, 27% (95% CI, 24%-31%) at 2 years, and 28%
(95 CI, 25%-32%) at 3 years after HLA-matched UD
allo-SCT (P 5 .06, .07, and .09, respectively). Table 4
shows the results of themultivariate analysis for relapse;
of note, the type of donor was not significant (RR, 0.81;
95% CI, 0.50-1.30; P 5 .38), whereas the variables
associated with higher relapse were CR2 at time of
transplantation (RR, 1.78; 95% CI, 1.13-2.81; P 5
.01), RIC/nonmyeloablative conditioning (RR, 1.50;
95%CI, 1.12-2.01;P\.01), and\12months fromdiag-
nosis to transplantation (RR, 0.56; 95% CI, 0.35-0.90;
Table 1. Patient, Disease, and Transplant Characteristics
MMRD HLA-Matched UD
Characteristic Number Evaluated n (%) Number Evaluated n (%) P Value
Number of patients 89 700
Age, median (range), years 89 35 (18-64) 700 43 (18-74) <.01
Sex 89 700 .50
Male 50 (56) 367 (52)
Female 39 (44) 333 (48)
Donor/recipient race match — 700 NA
Mismatched 42 (6)
Matched 616 (88)
Unknown 42 (6)
Karnofsky score before transplantation 89 700 .29
<90 24 (27) 158 (23)
$90 60 (67) 469 (67)
Unknown 5 (6) 73 (10)
Disease 89 700 .66
AML 59 (66) 480 (69)
ALL 30 (34) 220 (31)
Disease status 89 700 .26
CR1 61 (69) 437 (62)
CR2 28 (31) 263 (38)
AML cytogenetics 59 480 .63
Low 5 (8) 46 (10)
Intermediate/high 40 (68) 345 (72)
Unknown 14 (24) 89 (19)
ALL cytogenetics 30 220 <.01
Low 13 (43) 40 (18)
Intermediate/high 8 (27) 102 (46)
Unknown 9 (30) 78 (36)
Graft type 89 700 .35
Bone marrow 35 (39) 312 (45)
Peripheral blood 54 (61) 388 (55)
Conditioning regimen 89 700 .24
Ablative 73 (82) 535 (76)
RIC/nonmyeloablative 16 (18) 165 (24)
Use of ATG in conditioning 87 700 .16
No 72 (83) 616 (88)
Yes 15 (17) 84 (12)
GVHD prophylaxis 89 700 .01
CsA/tacrolimus ± others (no MTX) 10 (11) 158 (23)
CsA/tacromlimus + MTX 79 (89) 542 (77)
Time from diagnosis to transplantation, months, median (range) 89 7 (2-183) 699 7 (1-171) .12
Donor relationship 89 700 NA
Sibling 54 (61) —
Parent 15 (17) —
Child 13 (15) —
Other relative 7 (8) —
Unrelated — 700 (100)
HLA difference 88 700
HLA-A 39 (44) —
HLA-B 25 (28) —
HLA-DRB1 25 (28) —
ABO match 89 700 <.01
Matched 51 (57) 300 (43)
Minor mismatch 13 (15) 183 (26)
Major mismatch/bidirectional 19 (21) 217 (31)
Unknown 6 (7) 0
Donor/recipient sex match 89 700 .02
Male/male 26 (29) 266 (38)
Male/female 22 (25) 198 (28)
Female/male 24 (27) 101 (14)
Female/female 17 (19) 135 (19)
CMV match 89 700 <.01
D-/R- 20 (22) 217 (31)
D-/R+ 14 (16) 230 (33)
D+/R- 14 (16) 96 (14)
D+/R+ 41 (46) 141 (20)
Unknown 0 16 (2)
Donor age, year, median (range) 88 38 (9-71) 700 34 (18-60) .05
Year of transplantation 89 700 <.01
1995-2000 55 (62) 169 (24)
(Continued )
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Table 1. (Continued )
MMRD HLA-Matched UD
Characteristic Number Evaluated n (%) Number Evaluated n (%) P Value
2001-2005 34 (38) 531 (76)
Follow-up of survivors, months, median (range) 37 54 (3-135) 299 38 (10-149)
Deaths, n 52 401 NA
Primary disease 12 (23) 145 (36)
New malignancy 0 3 (1)
GVHD 9 (17) 48 (12)
IPN 7 (13) 18 (4)
Infection 9 (17) 78 (19)
Organ failure 8 (15) 84 (21)
Graft failure 1 (2) 1 (<1)
Hemorrhage 1 (2) 14 (3)
Accidental death 0 2 (<1)
Unknown 5 (10) 8 (2)
MMRD indicates mismatched related donor; UD, unrelated donor; AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; CR1, first
complete remission;CR2, second complete remission;CsA, cyclosporine;MTX,methotrexate;CMV, cytomegalovirus;GVHD, graft-versus-host disease.
644 Biol Blood Marrow Transplant 17:640-648, 2011D. Valca´rcel et al.P5 .02). Relapsewas the primary cause of death in both
groups (Table 1).TRM
The cumulative incidence of TRM was 34% (95%
CI, 24%-44%) at 1 year, 38% (95% CI, 28%-48%) at
2 years, and 39% (95% CI, 29%-50%) at 3 years after
MMRD allo-SCT and 24% (95% CI, 21%-27%) at 1
year, 27% (95% CI, 24%-31%) at 2 years, and 31%
(95% CI, 27%-34%) at 3 years after HLA-matched
UD allo-SCT (P 5 .07, .06, and .14, respectively).Table 2. Univariate Analysis
MMRD
Outcome Event n Probability (95% CI)
ANC >0.5  109/L 89
@28 days 89% (81%-95%)
@100 days 93% (87%-97%)
Platelets >20  109/L 89
@60 days 71% (61%-80%)
@100 days 75% (65%-83%)
Acute GVHD II-IV 86
@ 100 days 49% (38%-60%)
Acute GVHD III-IV 86
@ 100 days 22% (14%-32%)
Chronic GVHD 85
@ 1 year 35% (25%-46%)
TRM 86
@ 1 year 34% (24%-44%)
@ 2 year 38% (28%-48%)
@ 3 year 39% (29%-50%)
Relapse 86
@ 1 year 15% (8%-23%)
@ 2 year 19% (11%-28%)
@ 3 year 20% (12%-29%)
DFS 86
@ 1 year 51% (41%-62%)
@ 2 year 44% (33%-55%)
@ 3 year 41% (30%-52%)
OS 89
@ 1 year 57% (46%-67%)
@ 2 year 46% (35%-56%)
@ 3 year 42% (31%-52%)
MMRD indicates mismatched related donor; UD, unrelated donor; ANC, absol
related mortality; DFS, disease-free survival; OS, overall survival.Table 4 presents the results of the multivariate analysis
for TRM. There was no significant difference in
TRM in the two groups (RR, 1.14; 95% CI, 0.77-1.69:
P 5 .52). The only variables associated with increased
TRMwere older patient age (31-50 years vs 18-30 years;
RR, 1.47; 95%CI, 1.08-2.01; P5 .02) and transplanta-
tionbefore 2001 (RR, 1.64; 95%CI, 1.19-2.27:P\.01).DFS
The DFS was 51% (95% CI, 41%-62%) at 1 year,
44% (95% CI, 33%-55%) at 2 years, and 41% (95%HLA-Matched UD
n Probability (95% CI) P
700
93% (91%-95%) .21
95% (94%-97%) .43
700
81% (78%-84%) .05
85% (82%-87%) .04
695
47% (43%-51%) .71
698
15% (13%-18%) .15
690
47% (44%-51%) .03
698
24% (21%-27%) .07
27% (24%-31%) .06
31% (27%-34%) .14
698
23% (20%-26%) .06
27% (24%-31%) .07
28% (25%-32%) .09
698
53% (50%-57%) .74
46% (42%-49%) .74
41% (37%-45%) .93
700
61% (57%-64%) .51
50% (46%-54%) .49
44% (40%-48%) .65
ute neutrophil count; GVHD, graft-versus-host disease; TRM, treatment-
Table 3. Multivariate Analysis for Acute and Chronic GVHD
Acute GVHD II-IV* Acute GVHD III-IV† Chronic GVHD‡
Main Effect RR (95%CI) P RR (95%CI) P RR (95%CI) P
HLA-matched UD 1.00 1.00 1.00
MMRD 1.11 (0.80-1.55) .53 1.53 (0.91-2.57) .11 0.58 (0.39-0.85) <.01
GVHD indicates graft-versus-host disease; UD, unrelated donor; MMRD, mismatched related donor.
*The acute GVHD II-IV model was stratified on conditioning regimen and adjusted for CMV match (P 5 .02) and graft type (P < .01).
†Acute GVHD III-IV was adjusted for CMV match (P < .01), Karnofsky score (P < .01), ABO match (P5 .04), and time from diagnosis to transplantation
(P 5 .03).
‡Chronic GVHD was adjusted for ATG use in conditioning (P < .01), graft type (P < .01), and patient sex (P 5 .04).
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53% (95% CI, 50%-57%) at 1 year, 46% (95% CI,
42%-49%) at 2 years, and 41% (95% CI, 37%-45%)
at 3 years after HLA-matched UD allo-SCT (P 5 .74,
.74, and .93, respectively).Multivariate analysis revealed
no significant difference inDFSbetween the twogroups
(Table 4). The only factor associated with decreased
DFS was a Karnofsky score\90% (RR, 1.37; 95% CI,
1.10-1.69; P\ .01).
OS
OScurves are shown inFigure 3.OSprobabilitywas
57% (95% CI, 46%-67%) at 1 year, 46% (95% CI,
35%-56%) at 2 years, and 42% (95% CI, 31%-52%)
at 3 years after MMRD allo-SCT and 61% (95% CI,
57%-64%) at 1 year, 50% (95% CI, 46%-54%) at 2
years, and 44% (95% CI, 40%-48%) at 3 years after
HLA-matched UD allo-SCT (P 5 .51, .49, and .65,
respectively). As shown in Table 4, there was no signif-
icant association betweenOS and donor type. Variables
associated with decreased OS were older patient
age (31-50 years vs 18-30 years; RR, 1.34; 95% CI,
1.06-1.69; P 5 .01) and transplantation before 2001
(RR, 1.35; 95% CI, 1.05-1.72; P5 .02).
Subset Analyses
Inclusion of cell dose (total nucleated cells in BM
allo-SCT and mononuclear cells in PB allo-SCT)
was limited by missing data, but an analysis of available
data did not change our conclusions (data not shown).
No significant differences were identified between
class I mismatches and class II mismatches within theFigure 1. Relative risks of MMRD SCT versus HLA-matched UD SCT
(RR, 1.0) from multivariate analysis. Whiskers represent 95% CIs.one-antigen–MMRD group for all endpoints (data
not shown). Finally, no significant differences in out-
comes were identified when the comparison of the
HLA-matched UD and one-antigen–MMRD groups
were limited to the nonmyeloablative/RIC condition-
ing subset (data not shown).
DISCUSSION
BecauseHLAmatching is themost important vari-
able in allo-SCT [12,15,17], and current HLA typing
methods using high-resolution molecular techniques
have improved the results after UD allo-SCT over
the last 10 years [2], previously reported comparisons
between related and unrelated transplants may be out-
dated [19]. Some patients may have both an MMRD
and a high likelihood of having an 8/8 HLA-matched
UD, and for this group of patients, it is of interest to de-
termine whether a search for a UD should be initiated.
A key finding from the present study is that the
main outcomes of TRM, relapse, DFS, and OS were
similar in the HLA-matched UD and MMRD groups,
suggesting that the two alternatives are indeed compa-
rable. Although more patients in the MMRD group
received methotrexate as GVHD prophylaxis (89% vs
77%), GVHD prophylaxis was not statistically signifi-
cant in the univariate or multivariate analysis, and thus
it likely did not contribute to the difference in cGVHD
incidence. This finding is in agreement with previous
studies comparing the two donor sources [14,15].
The only observed difference was an increasedFigure 2. Unadjusted cumulative incidence of chronic GVHDby donor
type.
Table 4. Multivariate Analysis for Relapse, TRM, DFS, and OS
Relapse* TRM† DFS‡ OS§
Main Effect RR (95% CI) P RR (95% CI) P RR (95% CI) P RR (95% CI) P
HLA-matched UD 1.00 1.00 1.00 1.00
MMRD 0.81 (0.50-1.30) .38 1.14 (0.77-1.69) .52 1.06 (0.80-1.41) .69 0.99 (0.73-1.34) .94
TRM indicates treatment-related mortality; DFS, disease-free survival; OS, overall survival; UD, unrelated donor; MMRD, mismatched unrelated donor.
*The relapse model was adjusted for Karnofsky score at transplantation (P5 .03), conditioning regimen (P < .01),disease status (P5 .01), and time from
diagnosis to transplantation (P 5 .02).
†The TRMmodel was stratified by graft type and donor/recipient sex match and adjusted for patient age (P5 .05), and year of transplantation (P < .01).
‡The DFS model was adjusted for Karnofsky score at transplantation (P < .01).
§The OS model was stratified by graft type and adjusted for patient age at transplantation (P < .01) and year of transplantation (P 5 .02).
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SCT, a complication often leading to impaired quality
of life [31]. Taking this into account, and given the lack
of benefit in terms of DFS and OS, it is reasonable to
use the MMRD when available, instead of initiating
a UD search. Because this study was performed with
patients with acute leukemia in CR1 or CR2, our find-
ings are limited to these patients, and extension to pa-
tients with more advanced disease or other diseases
requires further investigation.
HLA is inherited following Mendelian genetics,
with two mechanisms explaining the availability of
a one-antigen MMRD. The first is crossing-over in
HLA genes, which occurs more frequently in class I,
because HLA-A loci are far from those encoding
HLA-B and HLA-C. The second is the presence of
HLA alleles or at least one haplotype in the patient
with high frequency in the overall population [28]. In
this situation, the likelihood of finding a related donor
sharing one HLA haplotype, with the other HLA
haplotype being identical except for one gene in the
extended family (eg, cousins, uncles, aunts), is in-
creased, but the additional delay because of extended
family typing must be balanced against the low likeli-
hood of finding a suitable related donor. One study
estimated that more than 30 individuals must be typed
to identify a one-antigen MMRD [1]. Tools are avail-
able for calculating the probability of finding a related
donor or a UD depending on HLA type, and consul-
ting with an HLA expert may be helpful [28-30].
Given all of these considerations, and the fact thatFigure 3. Unadjusted probability of OS by donor type.one-antigen–MMRD allo-SCT was associated with
similar clinical outcomes but with less cGVHD, one
suggested approach would be to use a one-antigen–
mismatched sibling if available but otherwise start
a UD search. Because only 13% of patients will have
an MMRD after extended family typing, with the aim
of shortening the time to transplantation, a suitable
strategy could be to perform a preliminary unrelated
search while the familiar study is being performed.
The significantly lower incidence of cGVHD in the
MMRD group observed in this study was unexpected,
given that HLA mismatch is known to predispose to
aGVHD and less strongly to cGVHD [17]. Other char-
acteristics also favoring this complication, suchas female
to male transplant, advanced age of the donor and/or
patient, and positive CMV serologic status, were more
frequent in the MMRD group. Previous studies found
a similar incidence of cGVHD in MMRD allo-SCT
and HLA-identical sibling allo-SCT [14]. Thus, the
higher incidence of cGVHD in the HLA-matched
UD group may be explained in part by undetected
disparities between donor and recipient other than in
HLA genes. Of note, most of these gene disparities
may involveminor histocompatibility antigens (mHAs),
which are increasingly associated with the development
of GVHD in the setting of HLA-identical sibling SCT
[32-34]. Because these antigens are frequently encoded
in chromosomes other than chromosome 6, it is likely
that UDs will differ in these mHAs more frequently
than related donors, especially if they are siblings.
Nevertheless, in a recent study from the CIBMTR,
mismatching in known mHAs was not associated with
a higher incidence of GVHD in patients who
underwent allo-SCT from a matched UD [35]. Al-
though that study is the largest to date evaluating the
role of mHAs in the unrelated setting, the small sub-
group size might have limited its power to detect differ-
ences. Moreover, a recent publication has emphasized
the importance of haplotype matching in the setting of
UD allo-SCT to avoid severe GVHD [36]. Because
most of the MMRD transplants reported here were
from one-antigen–mismatched siblings (and thus the
HLA difference might result from crossing-over), the
degree of extended haplotype matching is likely higher
than in the UD group.
Biol Blood Marrow Transplant 17:640-648, 2011 647One-Antigen MMRD versus HLA-Matched URD in Acute LeukemiaThis study has some limitations. The first is the
small number of patients in the MMRD group, which
likely reflects the preference of initiating a UD search
instead of an extended family search because it is time-
consuming and expensive and has a low probability of
success [1]. Nevertheless, this study included one of
the largest numbers of one-antigen–MMRD patients
analyzed in a single report. Another drawback of the
findings reported here is that, as in other retrospective
registry studies, there were differences between the
MMRD and UD groups in certain aspects important
to transplantation outcome, including age (younger
in the MMRD group) and year of transplantation (ear-
lier in the MMRD group) However, this latter limita-
tion was partially corrected for by performing the
multivariate analysis including these covariates and
showing a practically identical RR of TRM and OS
in the two groups. Of course, the only approach to
definitively answering the question would be a ran-
domized prospective comparison of the two transplan-
tation alternatives, which is highly unlikely.
A third limitationof the study is thatHLA-matching
assessment of related donors was based on low-
resolution typing and limited to HLA-A, -B, and
-DRB1. This is the current practice in most institutions
for related donor selection, however. Because informa-
tion on HLA-C and HLA-DQ was not available, it is
not possible to rule out additional mismatches in the
related donor group. This is unlikely in most cases
affecting HLA-A (n 5 39; 44%), because linkage dis-
equilibrium means that matching at HLA-B (n 5 25;
28%) and -DR (n 5 25; 28%) is generally associated
with matching at HLA-C and -DQ. Nevertheless, it
seems reasonable to recommend the study of at least
HLA-C in patients with a mismatch in HLA-B.
Although the numbers were small, the outcomes of class
Imismatchversus class IImismatchwithinone-antigen–
MMRDtransplantswere similar regarding all endpoints
studied, which is in agreement with a previous Japanese
study that included 112 MMRDs [11]. On the other
hand, because ofmissingdata,wewereunable to analyze
the possible impact of KIR ligandmismatches or nonin-
herited maternal or paternal antigens, aspects that have
been recently considered in donor selection.
In conclusion, our data support the conclusion that
both MMRD and HLA-matched UD are acceptable
for transplantation in patients who require allo-SCT
and lack an HLA-identical sibling. The lower incidence
of cGVHD after MMRD allo-SCT, the easy and rapid
access to relatives, and the lower cost make the MMRD
modality the first option to consider, if available.ACKNOWLEDGMENTS
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